ClinicalTrials.Veeva

Menu

A Study With Central Nervous System Metastatic EGFR Mutation Positive Non-small Cell Lung Cancer

H

Hunan Province Tumor Hospital

Status

Enrolling

Conditions

NSCLC

Study type

Observational

Funder types

Other

Identifiers

NCT05991193
FORCE RWS

Details and patient eligibility

About

This is a descriptive observational study, in which data are collected in an epidemiological fashion and prospective. This study does not intend to intervene the current medical practice of the recruited patients.

Full description

This is a descriptive observational study, in which data are collected in an EGFR mutant NSCLC. Our research plan aims to use multi-omics approaches to predict the likelihood of patients developing brain metastases, assess the prognosis of brain metastasis treatment, and identify potential biomarkers.

Enrollment

100 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients must be ≥18 years.
  • Provision of fully informed consent prior to any study specific procedures.
  • Patient with EGFR 19Del or L858R mutation diagnosed histologically or cytologically. The mutations above may exist alone or together.
  • Patients must have untreated advanced Non-Small Cell Lung Cancer (NSCLC).
  • According to the RECIST 1.1 standard, the patient must have at least one measurable lesion.

Exclusion criteria

  • None

Trial contacts and locations

1

Loading...

Central trial contact

Nong Yang, MD; Yongchang Zhang, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems